Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in cone photoreceptor cells | 0.75 |
| chemistry Open Targets | compounds already reach it: padsevonil | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 123 | 0.73 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7869
Sealed predictions
- SV2B in dopamine neurons, braak+0.61 (p 0.078) → -0.05 (p 0.893)receipt 7877
Swarm cases
receipt 7877: SV2B in dopamine neurons, braak
- power
- full sample +0.26 (p 0.298, n 18), 95% CI -0.24 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.27 (p 0.281, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.328, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.40, sign flips 0; without severely affected donors +0.26 (p 0.298, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SV2B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts